School project · Delayed data · Not financial adviceTerms
SingularityViewAll companies

Stock research

IOVANCE BIOTHERAPEUTICS, INC. IOVA

Healthcare · Biotechnology

$14.62last close 2026-10-09 · market cap $6.62B · delayed data

Trailing returns

1M+73.43%
3M+234.55%
6M+264.59%
1Y+567.58%
5Y-44.66%

Basis: Adjusted daily closes.

What it does

Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally.

Open IOVA in the live terminal →

Valuation, cost of capital, SEC filings, ownership and more, with the source named on every figure.

Post on XLinkedInEmail

Where these figures come from

Delayed data. Not financial advice. Figures are read from the sources above at the dates shown; nothing here is a recommendation. Disclosures · All companies